LB Pharmaceuticals To Participate In Upcoming September Investor Events
Wells Fargo 21st Annual Healthcare Conference
- 1x1 investor meetings on Wednesday, September 9, 2026, in Boston, MA
H.C. Wainwright 28th Annual Global Investment Conference
- Presentation will be available virtually at 10:00 a.m. ET on Monday, September 14, 2026 Virtual 1x1 investor meetings on Monday, September 14, 2026
TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit
- Virtual fireside chat at 2:30 p.m. ET on Wednesday, September 23, 2026
The webcasts for the presentation and fireside chat will be available on the“Investors” page section under the“Events” section of the Company's website at , where a replay of the webcasts will be archived.
About LB Pharmaceuticals
LB Pharmaceuticals is a neuromedicines company dedicated to developing and commercializing high-impact therapies that address the multiple dimensions of underserved brain diseases. The Company is building a pipeline that leverages the broad therapeutic potential of its lead product candidate, LB-102, which the Company believes has the opportunity to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102, if approved, has the potential to become a mainstay of psychiatric practice by offering a balanced clinical activity and tolerability profile that provides a potentially attractive alternative to branded and generic therapeutics for the treatment of a broad range of neuropsychiatric diseases.
Media and Investor Contact:
Ellen Rose
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment